The Journal of Internal Korean Medicine (대한한방내과학회지)

The Society of Internal Korean Medicine (대한한방내과학회)
권호 표지
DOI QR코드

DOI QR Code

Yukgunja-tang for Irritable Bowel Syndrome: A Protocol for a Systematic Review and Meta-Analysis

  • Kangwook Lee (Dept. of Clinical Korean Medicine, Graduate school of Kyung Hee University) ;
  • Seok-Jae Ko (Dept. of Gastroenterology, College of Korean Medicine, Kyung Hee University) ;
  • Minjeong Kim (Dept. of Clinical Korean Medicine, Graduate school of Kyung Hee University) ;
  • Chaehyun Park (Dept. of Clinical Korean Medicine, Graduate school of Kyung Hee University) ;
  • Min-Seok Cho (Dept. of Clinical Korean Medicine, Graduate school of Kyung Hee University) ;
  • Jae-Woo Park (Dept. of Gastroenterology, College of Korean Medicine, Kyung Hee University)
  • Received : 2023.04.10
  • Accepted : 2023.06.19
  • Published : 2023.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Irritable bowel syndrome (IBS) is a digestive disorder characterized by abdominal discomfort or pain accompanied by a change in stool condition. Owing to its complicated mechanisms, a standard treatment for IBS has not yet been established. Yukgunja-tang (YGT) is a Korean herbal medicine known in Asia to be effective in the treatment of gastrointestinal symptoms. In this study, we will conduct a systematic review of randomized controlled trials (RCTs) to assess the efficacy and safety of YGT in IBS treatment. Methods and analysis: English databases, such as Embase, Medline (via PubMed), Allied and Complementary Medicine Database, and Cochrane Central Register of Controlled Trials, will be searched for articles published up to April 2023. Additional databases, such as five Korean, one Chinese, and one Japanese database, will be included. RCTs and quasi-RCTs will also be included in the assessment of the efficacy of YGT. The overall efficacy rate will be the primary outcome, and data such as IBS quality-of-life measurements, global symptom scores, and adverse events will be the secondary outcomes. Review Manager Version 5.3 will be used for evaluation, and the risk of bias (RoB) will be evaluated using Cochrane Collaboration's RoB tool. The Grading of Recommendations Assessment, Development, and Evaluation approach will be used to score the quality of evidence. Conclusion: This study will demonstrate the efficacy and safety of YGT for treating patients with IBS.

Keywords

Acknowledgement

This work was supported by a National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT) (No. 2022R1C1C1004937) to S.J.K., and by the Bio & Medical Technology Development Program of the National Research Foundation (NRF) funded by the Korean government (MSIT) (No. 2022M3A9E4082682) to J.W.P..

References

  1. Drossman DA. Functional gastrointestinal disorders: history, pathophysiology, clinical features, and Rome IV. Gastroenterology 2016;150(6):1262-79. https://doi.org/10.1053/j.gastro.2016.02.032
  2. Ford AC, Sperber AD, Corsetti M, Camilleri M. Irritable bowel syndrome. The Lancet 2020;396(10263):1675-88. https://doi.org/10.1016/S0140-6736(20)31548-8
  3. Oka P, Parr H, Barberio B, Black CJ, Savarino EV, Ford AC. Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2020;5(10):908-17. https://doi.org/10.1016/S2468-1253(20)30217-X
  4. Muscatello MR, Bruno A, Mento C, Pandolfo G, Zoccali RA. Personality traits and emotional patterns in irritable bowel syndrome. World J Gastroenterol 2016;22(28):6402-15. https://doi.org/10.3748/wjg.v22.i28.6402
  5. Trinkley KE, Nahata MC. Treatment of irritable bowel syndrome. J Clin Pharm Ther 2011;36(3):275-82. https://doi.org/10.1111/j.1365-2710.2010.01177.x
  6. Ford AC, Moayyedi P, Chey WD, Harris LA, Lacy BE, Saito YA, et al. American college of gastroenterology monograph on management of irritable bowel syndrome. Am J Gastroenterol 2018;113(suppl 2):1-18. https://doi.org/10.1038/s41395-018-0084-x
  7. Ko SJ, Han GJ, Kim SK, Seo JG, Chung WS, Ryu BH, et al. Effect of Korean herbal medicine combined with a probiotic mixture on diarrhea-dominant irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial. Evid Based Complement Alternat Med 2013;2013:824605.
  8. Sujuki H, Matsuzaki J, Fukushima Y, Suzaki F, Kasugai K, Nishizawa T, et al. Randomized clinical trial: Rikkunshito in the treatment of functional dyspepsia-a multicenter, double-blind, randomized, placebo-controlled study. Neurogastroenterol Motil 2014;26(7):950-61. https://doi.org/10.1111/nmo.12348
  9. Wu Q. The Golden Book of the Medical Order. Great China Book Company; 1971, p. 107-8.
  10. Ko SJ, Park JW, Lee JH, Lee JE, Ha NY, Nam SU, et al. An Herbal Medicine, Yukgunja-Tang is more Effective in a Type of Functional Dyspepsia Categorized by Facial Shape Diagnosis: A Placebo-Controlled, Double-Blind, Randomized Trial. Evid Based Complement Alternat Med 2018;2018:8546357.
  11. Drossman DA, Hasler WL. Rome IV-functional GI disorders: disorders of gut-brain interaction. Gastroenterology 2016;150(6):1257-61. https://doi.org/10.1053/j.gastro.2016.03.035
  12. Lacy BE, Patel NK. Rome criteria and a diagnostic approach to irritable bowel syndrome. J Clin Med 2017;6(11):99.
  13. Li B, Liang L, Deng H, Guo J, Shu H, Zhang L. Efficacy and safety of probiotics in irritable bowel syndrome: A systematic review and meta-analysis. Front Pharmacol 2020;11:332.
  14. Shih YS, Tsai CH, Li TC, Lai HC, Wang KT, Liao WL, et al. The effect of Xiang-Sha-Liu-Jun-Zi tang (XSLJZT) on irritable bowel syndrome: A randomized, double-blind, placebo-controlled trial. J Ethnopharmacol 2019;238:111889.
  15. Cheng CW, Wu TX, Shang HC, Li YP, Altman DG, Moher D, et al. CONSORT extension for Chinese herbal medicine formulas 2017: Recommendations, explanation, and elaboration. Ann Intern Med 2017;167(2):112-21. https://doi.org/10.7326/M16-2977
  16. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The cochrane collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.
  17. Schunemann H, Brozek J, Guyatt G, Oxman A. GRADE Handbook. 2013. Available at http://gdt.gradepro.org/app/handbook/handbook.html. Accessed December 15, 2022.
  18. Sperber AD, Dumitrascu D, Fukudo S, Gerson C, Ghoshal UC, Gwee KA, et al. The global prevalence of IBS in adults remains elusive due to the heterogeneity of studies: a Rome Foundation working team literature review. Gut 2017;66(6):1075-82. https://doi.org/10.1136/gutjnl-2015-311240
  19. Wang Y, Huang YQ, Zhu SL, Zhang CR, Chen XL, Hou QK, et al. Efficacy of Tong-Xie-Yao -Fang granule and its impact on whole transcriptome profiling in diarrhea-predominant irritable bowel syndrome patients: study protocol for a randomized controlled trial. Trials 2020;21(1):908.
  20. Xu JP. Effect of Xiangsha Liu-Jun-Zi-Tang Decoction on Irritable Bowel Syndrome. Journal of health for all 2018;02:141.
  21. Gou YC. Clinical Observation on the treatment of Diarrhea-type Irritable Bowel Syndrome with Si-ni-san plus Xiangsha Liu-Jun-Zi-Tang Decoction in Liver Depression and Spleen Deficiency syndrome. Journal of traditional Chinese internal medicine 2013;5:56.
  22. Xiao Y, Liu YY, Yu KQ, Ouyang MZ, Luo R, Zhao XS. Chinese herbal medicine liu jun zi tang and Xiang sha liu jun zi tang for functional dyspepsia: meta-analysis of randomized controlled trials. Evid Based Complement Altern Med 2012;2012:936459.